The Bill & Melinda Gates Foundation, Wellcome and Mastercard have announced commitment totaling $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments.
The partners are committed to equitable access, including making products available and affordable in low-resource settings. The Gates Foundation and Wellcome are each contributing up to $50 million, and the Mastercard Impact Fund has committed up to $25 million to catalyze the initial work of the accelerator. The Gates Foundation’s funding is part of its $100 million commitment to the COVID-19 response announced last month.
The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and re-purposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. Currently there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and none approved for use on COVID-19.
Chief Executive Officer of the Bill & Melinda Gates Foundation, Mark Suzman said, “Viruses like COVID-19 spread rapidly, but the development of vaccines and treatments to stop them moves slowly. If we want to make the world safe from outbreaks like COVID-19, particularly for those most vulnerable, then we need to find a way to make research and development move faster. That requires governments, private enterprise, and philanthropic organizations to act quickly to fund R&D.”
(Ad) Stop getting irritated with excessing advertisements. View the information you want quickly on a clean, ad-free and exclusive Member Dashboard that offers tools to search for grants, view latest grant opportunities, upcoming deadlines, sample proposals, downloadable ebooks and also organize your favourites! Learn more.
Vice Chairman of Mastercard, Mike Froman said, “We’re proud to join this crucial effort to combat COVID-19 in furtherance of our commitment to inclusive growth. This global challenge not only represents a risk to the health and safety of populations all over the world, but also poses a potential disruption to the economic vitality of millions of people, businesses, and organizations worldwide. Our experience with financial inclusion shows us the importance of building a network of parties who bring not only their capital, but complementary assets and skill sets to the table, and we welcome other partners concerned about inclusive growth to join this effort.”
Therapeutics Accelerator will coordinate R&D efforts and remove barriers to drug development and scale-up to address the epidemic. It will work with the World Health Organization, government and private sector funders and organizations, as well as the global regulatory and policy-setting institutions.
(Ad) Are you still finding it difficult to search for donors online? Join Premium and use our powerful Donor Search mechanism to find relevant donors based on your country and location or keyword. Our specially developed algorithm will search across the internet for the most relevant and useful donors of your interest willing to fund your work. Learn more.
The Accelerator will have an end-to-end focus, from drug pipeline development through manufacturing and scale-up. By sharing research, coordinating investments, and pooling resources, these efforts can help to accelerate research.
By providing fast and flexible funding at key stages of the development process, the Accelerator will de-risk the pathway for new drugs and biologics for COVID-19 and future epidemic threats, ensuring access in lower-resource countries.
(Ad) Not able to keep track of so may different grant opportunities and their deadlines? No problem! fundsforNGOs Premium has a handy tool called "Deadline Calendar." This tool will help you keep track of all upcoming grant opportunities and their deadlines and view them in a beautiful calendar format. Learn more.
The COVID-19 Therapeutics Accelerator will operate jointly as an initiative of the funders, drawing on expertise from inside and outside their organizations. The Accelerator will pursue several aspects of the development cycle to streamline the pathway from candidate product to clinical assessment, use, and manufacturing.
To identify candidate compounds, the Accelerator will take a three-pronged approach: testing approved drugs for activity against COVID-19, screening libraries of thousands of compounds with confirmed safety data and considering new investigational compounds and monoclonal antibodies.
(Ad) Are you looking for readymade proposals? fundsforNGOs Premium has a vast collection of Sample Proposals from successful grantees around the world. These proposals are available for viewing so that you can quickly get new ideas, best practices, lessons learned and develop your proposal in the perfect manner. Learn more.
Drugs or monoclonal antibodies that pass initial screening would then be developed by an industry partner. The biotech and pharmaceutical industries will be critical partners, bringing their compound libraries and clinical data to the collaboration and lending commercialization and other expertise that will be required to scale up successful drugs and monoclonal antibodies.
Director of Wellcome, Dr. Jeremy Farrar said, “This virus is an unprecedented global threat, and one for which we must propel international partnerships to develop treatments, rapid diagnostics, and vaccines. Science is moving at a phenomenal pace against COVID-19, but to get ahead of this epidemic we need greater investment and to ensure research co-ordination. The Therapeutics Accelerator will allow us to do this for potential treatments with support for research, development, assessment, and manufacturing.”
(Ad) How to raise funds? Where can I find a list of donors for my area of work? How to write proposals? How can I submit a grant request to USAID, the European Commission or the Gates Foundation? How can I use Social Media to promote my work? We have developed powerful resources in the form of Ebook and Articles covering all this information and more. Learn more.
“COVID-19 is an extremely challenging virus, but we’ve proved that through collaborating across borders we can tackle emerging infectious diseases. We must strive to strengthen efforts in the face of COVID-19, and in doing so, continue to make sure advances are accessible and affordable to all. Investing now, at scale, at risk and as a collective global effort is vital if we are to change the course of this epidemic. We welcome others to join us in this effort.”
In parallel to the development of the COVID-19 drug pipeline, the Accelerator will work with regulators to align criteria and develop manufacturing capacity with industry. An accelerated pathway to bringing effective treatments to patients is around one year for products that have current regulatory approval or candidates with existing clinical data. The timeline would be longer for compounds further upstream in the pipeline that have limited existing clinical data.
While antiviral drugs are approved to lessen the severity of seasonal flu and treat HIV, among other viral diseases, none have demonstrated efficacy against the current epidemic. One reason for the lack of effective treatments is that products may not have an immediate market, which can slow or prevent their research and commercial development.
The COVID-19 Therapeutics Accelerator is designed to help by bringing together resources and expertise to lower the financial and technical risk for academia, biotech, and pharmaceutical companies, while ensuring that these products are accessible and affordable to people in low-resource settings. The expertise of pharmaceutical companies will be critical in identifying, researching, and commercializing successful drugs.
About the Bill & Melinda Gates Foundation
(Ad) Are you fed up of receiving non-relevant, non-useful and pointless funding alerts and updates in your email? Not anymore! With fundsforNGOs Premium, you can configure what type of funding updates you want to receive, select specific countries and areas of work and receive information only about them. Save your time by getting the most relevant and useful updates in your email. Learn more.
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life.
(Ad) How will you feel when you view grants for all countries around the world? fundsforNGOs Premium has a World Map of Grants that offers open and live grants for all the countries in one single view. Click on any country, and you can view the latest grants updated in real-time. Learn more.
Wellcome exists to improve health by helping great ideas to thrive. They support researchers, take on big health challenges, they campaign for better science, and help everyone get involved with science and health research. They are a politically and financially independent foundation.
(Ad) There are so many NGO Jobs, but what about for my country and area of work? fundsforNGOs Premium has a "Jobs Database" where you can not only search jobs but also receive job alerts in your email based on your country (or countries) and areas of your profession. Learn more.
Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart, and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments, and businesses realize their greatest potential.